TSX:EDT - Post Discussion
Post by
TechOne on Nov 21, 2024 1:52pm
Spectral on Linkedin Today
Endotoxic Septic Shock (ESS) affects over 120,000 people annually in the United States, marking the advanced and most severe stage of sepsis. ESS poses immense treatment challenges due to elevated bacterial endotoxins and critical organ failures, including the cardiovascular and renal systems. At Spectral Medical, we are committed to transforming patient outcomes in ESS through a personalized, innovative approach. By combining a precise diagnostic test with a cutting-edge therapy to remove endotoxins from the bloodstream, we aim to address this life-threatening condition effectively. Our innovative approach is presently undergoing a phase 3 clinical trial and was featured on @BalancingActTV, where researchers, physicians, and clinical trial experts shared insights into this promising therapy. Together, we strive to redefine the standard of care for ESS and offer hope to patients and their families. Watch the episode https://lnkd.in/dfRygdSB
Be the first to comment on this post